[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.180.70. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

February 1, 2017, Vol 3, No. 2, Pages 143-281

In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2017;3(2):143. doi:10.1001/jamaoncol.2016.1669
Viewpoint

Noncolorectal Gastrointestinal Cancers—What Did We Learn in 2016?

Abstract Full Text
JAMA Oncol. 2017;3(2):157-158. doi:10.1001/jamaoncol.2016.3728

This Viewpoint highlights recent findings in noncolorectal gastrointestinal cancer treatments.

Highlights of Recent Studies of Metastatic Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2017;3(2):159-160. doi:10.1001/jamaoncol.2016.3676

This Viewpoint highlights ASCO presentations of recent findings in studies of metastatic non–small cell lung cancer.

Editorial

Human Papillomavirus–Associated Oropharyngeal CancerNot Just White Men Anymore

Abstract Full Text
JAMA Oncol. 2017;3(2):161-162. doi:10.1001/jamaoncol.2016.3510

Long-term Adjuvant Tamoxifen Therapy and Decreases in Contralateral Breast Cancer

Abstract Full Text
JAMA Oncol. 2017;3(2):163-164. doi:10.1001/jamaoncol.2016.3324

Primary Tumor Sidedness as Prognostic and Predictive Biomarker in Metastatic Colorectal CancerFurther Validation of a Potentially Practice-Changing Variable

Abstract Full Text
JAMA Oncol. 2017;3(2):165-166. doi:10.1001/jamaoncol.2016.3777
Original Investigation

Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method

Abstract Full Text
JAMA Oncol. 2017;3(2):169-177. doi:10.1001/jamaoncol.2016.3067

This cohort study explores the role of human papillomavirus status in patients with head and neck squamous cell cancer, stratified by race/ethnicity, sex, and oropharyngeal squamous cell carcinoma vs nonoropharyngeal head and neck squamous cell carcinoma.

Immune Response to HPV16 E6 and E7 Proteins and Patient Outcomes in Head and Neck Cancer

Abstract Full Text
JAMA Oncol. 2017;3(2):178-185. doi:10.1001/jamaoncol.2016.4500

This population-based study of patients with head and neck cancer investigates whether immunologic response to human papillomavirus 16 is associated with patient survival across anatomic sites, independent of smoking and drinking history.

Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting

Abstract Full Text
has multimedia
JAMA Oncol. 2017;3(2):186-193. doi:10.1001/jamaoncol.2016.3340

This cohort study investigates the association between adjuvant tamoxifen and aromatase inhibitor therapy and contralateral breast cancer risk.

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal CancerRetrospective Analyses of the CRYSTAL and FIRE-3 Trials

Abstract Full Text
JAMA Oncol. 2017;3(2):194-201. doi:10.1001/jamaoncol.2016.3797

This secondary analysis of the CRYSTAL and FIRE-3 trials examines the prognostic and predictive value of primary tumor location in patients with metastatic colorectal cancer treated with fluorouracil, leucovorin, and irinotecan plus cetuximab.

Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid CancerGenetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality

Abstract Full Text
JAMA Oncol. 2017;3(2):202-208. doi:10.1001/jamaoncol.2016.3288

This genetic-clinical correlation study assesses the prognostic power of the genetic duet of BRAF V600E and TERT promoter mutations in papillary thyroid cancer–specific mortality.

Prognostic Survival Associated With Left-Sided vs Right-Sided Colon CancerA Systematic Review and Meta-analysis

Abstract Full Text
has active quiz
JAMA Oncol. 2017;3(2):211-219. doi:10.1001/jamaoncol.2016.4227

This systematic review and meta-analysis examines the prognostic value of primary tumor sidedness (right vs left) in colon cancer.

Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck CarcinomaA Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2017;3(2):220-226. doi:10.1001/jamaoncol.2016.4510

This randomized clinical trial of patients with locoregionally advanced squamous cell carcinoma of the head and neck compared the effect of accelerated-fractionation radiotherapy (RT) plus the anti–epidermal growth factor receptor antibody panitumumab vs standard-fractionation RT plus high-dose cisplatin on progression-free survival.

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 TherapyA Secondary Analysis of the NeoALTTO Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2017;3(2):227-234. doi:10.1001/jamaoncol.2016.3824

This secondary analysis of the NeoALTTO trial uses RNA sequencing data to investigate the ability of clinically and biologically relevant genes and gene signatures to predict the efficacy of anti-HER2 agents.

Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular CarcinomaAnalysis of REACH Trial Results by Child-Pugh Score

Abstract Full Text
open access
JAMA Oncol. 2017;3(2):235-243. doi:10.1001/jamaoncol.2016.4115

This analysis of findings of a randomized, double-blind, phase 3 trial assesses treatment effects and tolerability of ramucirumab by Child-Pugh score in patients with hepatocellular cancer enrolled from 154 global sites.

The Molecular Landscape of Recurrent and Metastatic Head and Neck CancersInsights From a Precision Oncology Sequencing Platform

Abstract Full Text
JAMA Oncol. 2017;3(2):244-255. doi:10.1001/jamaoncol.2016.1790

This study examines the distinct biology of recurrent and metastatic head and neck cancers and reviews implementation of precision oncology for patients with advanced disease.

Brief Report

A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1

Abstract Full Text
JAMA Oncol. 2017;3(2):256-259. doi:10.1001/jamaoncol.2016.3015

This clinical pathology study evaluates whether 4 commercially available drug-matched companion diagnostic PD-L1 antibody tests produce the same results when tested against lung cancer specimens with known range of expression of PD-L1.

Invited Commentary

Mutational Markers and Risk Stratification in Thyroid Cancer—The Art of War Refined

Abstract Full Text
JAMA Oncol. 2017;3(2):209-210. doi:10.1001/jamaoncol.2016.3286
Review

The Role of Genetic Testing in the Selection of Therapy for Breast CancerA Review

Abstract Full Text
JAMA Oncol. 2017;3(2):262-268. doi:10.1001/jamaoncol.2016.2719

This narrative review summarizes the current state of genomic testing for somatic mutations in breast cancer and considers approaches for more effective implementation.

From The JAMA Network

Preserving Neurocognition in Patients With Brain Metastases

Abstract Full Text
JAMA Oncol. 2017;3(2):269-270. doi:10.1001/jamaoncol.2016.3944

This randomized trial assessed whether patients with 1 to 3 brain metastases who received stereotactic radiosurgery (SRS) alone vs SRS combined with whole brain radiotherapy (WBRT) had less cognitive deterioration at 3 months.

JAMA Oncology Clinical Challenge

An Aggressive Mandibular Mass

Abstract Full Text
JAMA Oncol. 2017;3(2):271-272. doi:10.1001/jamaoncol.2016.5648

A woman in her 70s presented with progressive supraclavicular, facial, and mandibular swelling of 3 months’ duration; a fixed mass throughout the left preauricular space; and a right supraclavicular mass. What is your diagnosis?

Research Letter

Ocular Toxicity of Mitogen-Activated Protein Kinase Inhibitors

Abstract Full Text
JAMA Oncol. 2017;3(2):275-277. doi:10.1001/jamaoncol.2016.4213

This study describes the ocular toxic effects of 3 different mitogen-activated protein kinase inhibitors currently at independent stages of clinical development.

The Rising Price of Cancer Drugs—A New Old Problem?

Abstract Full Text
JAMA Oncol. 2017;3(2):277-278. doi:10.1001/jamaoncol.2016.4275

This study examines 5-year trends in Medicare data and compares prices for older cancer drugs with prices for newer cancer drugs.

Comment & Response

Potential Benefit of Low-Dose Candesartan in Trastuzumab-Induced Cardiotoxic Effects

Abstract Full Text
JAMA Oncol. 2017;3(2):279. doi:10.1001/jamaoncol.2016.3637

Potential Benefit of Low-Dose Candesartan in Trastuzumab-Induced Cardiotoxic Effect—Reply

Abstract Full Text
JAMA Oncol. 2017;3(2):279-280. doi:10.1001/jamaoncol.2016.3595

Androgen Deprivation Therapy and Dose-Escalated Radiotherapy for Intermediate- and High-Risk Prostate CancerSign of Changing Times?

Abstract Full Text
JAMA Oncol. 2017;3(2):280-281. doi:10.1001/jamaoncol.2016.3987

Androgen Deprivation Therapy and Dose-Escalated Radiotherapy for Intermediate- and High-Risk Prostate Cancer—Reply

Abstract Full Text
JAMA Oncol. 2017;3(2):281. doi:10.1001/jamaoncol.2016.3974
Correction
Poetry and Oncology

Addressing Spiritual Distress

Abstract Full Text
JAMA Oncol. 2017;3(2):193. doi:10.1001/jamaoncol.2016.3699

17 Lines About Chemo

Abstract Full Text
JAMA Oncol. 2017;3(2):255. doi:10.1001/jamaoncol.2016.3645
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2017;3(2):144. doi:10.1001/jamaoncol.2016.1670
×